10-year

10-Year Anniversary Promotion (20% off)

Join GuruFocus Premium Membership Now for Only $279/Year

Once a decade discount

Save up to $500 on Global Membership.

Don't Miss It !

Free 7-day Trial
All Articles and Columns »

CurtissWright Corp. (CW) CEO Martin R Benante sells 6,058 Shares

November 22, 2010 | About:
insider

insider

57 followers
CEO of CurtissWright Corp. (CW) Martin R Benante sells 6,058 shares of CW on 11/18/2010 at an average price of $29.54 a share.

Curtisswright Corp. has a market cap of $1.37 billion; its shares were traded at around $29.8 with a P/E ratio of 13.13 and P/S ratio of 0.76. The dividend yield of Curtisswright Corp. stocks is 1.07%. Curtisswright Corp. had an annual average earning growth of 18.4% over the past 10 years.

CW is in the portfolios of Richard Aster Jr of Meridian Fund, Mario Gabelli of GAMCO Investors, Richard Pzena of Pzena Investment Management LLC, Kenneth Fisher of Fisher Asset Management, LLC, Paul Tudor Jones of The Tudor Group, Chuck Royce of Royce& Associates.

CFO Recent Trades:



  • Sell: Vice President and CFO Glenn E Tynan sold 1,227 shares of CW stock on 11/11/2010 at the average price of 30.52. Glenn E Tynan owns at least 33,110 shares after this. The price of the stock has decreased by 2.36% since.



This is the insider trade history vs. stock price of CW. For the complete insider trading history of CW, click here.




Directors and Officers Recent Trades:



  • Sell: Director William W Dr Sihler sold 2,337 shares of CW stock on 06/21/2010 at the average price of 31.66. William W Dr Sihler owns at least 6,724 shares after this. The price of the stock has decreased by 5.87% since.


About the author:

insider
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 4.5/5 (2 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK